ATOS (Atossa Therapeutics Inc.) stock: $2.12, $21.2M market cap, $26.1M cash, -$4.9M EV, $31.1M fully diluted market cap. Next expected readout: Nov-26. Lead program: (Z)-endoxifen (Breast Neoplasms), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions. Our lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/ selective estrogen receptor degrader (SERM/D) currently in Phase 2 clinical development.
Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead candidate in four Phase 2 trials; no discontinuation disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.